Real-World Evidence Collaborative

Real-World Evidence Collaborative

Randomized controlled trials (RCTs) are traditionally used by the US Food and Drug Administration (FDA) to evaluate a product’s safety and effectiveness. While they are the gold-standard from a research perspective, they are resource-intensive, requiring significant financial, time, and human capital investments. Coupled with unmet clinical needs and drug access challenges, the demands of RCTs have fueled patients and legislators to issue a call to action for new ways to optimize the drug development process so that the delivery of effective drugs to the marketplace is accelerated while the public’s safety remains ensured.

Health care stakeholders are enthusiastic about exploring whether patient information that is already captured at the point of care could inform and speed the development of new drugs. Called real-world data (RWD), analyzing this burgeoning information source has the potential to provide real-world evidence (RWE), information on the use of drugs and their outcomes and to understand whether they are performing as intended in routine care.

The 21st Century Cures Act and the sixth Prescription Drug User Fee Act (PDUFA VI) set milestones for FDA to explore the use of RWE in regulatory decision-making. To inform FDA as it works to meet these milestones, the Duke-Margolis Center for Health Policy RWE Collaborative engages stakeholders to guide high-priority efforts aimed at improving the development and use of RWE. The Collaborative also strives to drive progress in the use of real-world data and evidence to improve patient treatment options and outcomes more broadly. Guided by an advisory group consisting of leaders representing medical product developers, payers, research groups, providers, patient networks, and regulators, the RWE Collaborative is interested in the following 2021 priorities:

  • Embedding Practical Trials in Routine Care Delivery
  • Identifying Shared Real-World Evidentiary Opportunities
  • Developing Master RWE Protocols for Key Research Questions
  • PGHD Pilot Implementation Case Studies

To learn more about the RWE Collaborative or to learn more about 2020 projects, please contact Rachele Hendricks-Sturrup at


Advisory Group

Aylin Altan, Senior Vice President of Research, OptumLabs

Marc Berger, Co-Chair, Special Advisor for Real World Evidence, ISPOR

Barbara Bierer, Faculty Director, Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard

Brian Bradbury, Vice President, Center for Observational Research, Amgen

William Capra, Senior Director, Data Science, Roche Pharmaceuticals, Genentech

Adrian Cassidy, Global Head RWE, Novartis Pharmaceuticals Corporation

William Crown, Distinguished Research Scientist, The Heller School for Social Policy and Management at Brandeis University

Riad Dirani, Vice President, Global Health Economics and Outcomes Research, Teva Pharmaceuticals

Nancy Dreyer, Chief Scientific Officer & Senior Vice President, IQVIA

Andrew Emmett, FDA Liaison, Global Regulatory Policy & Intelligence, Pfizer

Carlos Garner, Vice President, Global Regulatory Affairs, Eli Lilly and Company

John Graham, Senior Vice President, Medical Engagement and Value Evidence & Outcomes, GlaxoSmithKline

Solomon Iyasu, Vice President, Head of Pharmacoepidemiology, Center for Observational and Real World Evidence, Merck & Co.

Ryan Kilpatrick, Head, Global Epidemiology, AbbVie

Christina Mack, RWE Task Force, ISPE

Subhara Raveendran, Senior Research Scientist, PatientsLikeMe

Irene Nunes, Vice President, Regulatory Affairs, Flatiron Health

Sally Okun, SallyOkun360

Bray Patrick-Lake, Director, Strategic Partnerships, Evidation

Eleanor Perfetto, Senior Vice President, Strategic Initiatives, National Health Council

Richard Platt, Executive Director, Harvard Pilgrim Health Care Institute and Chair, Department of Population Medicine, Harvard Medical School

Jeremy Rassen, Co-Founder, President, Chief Science Officer, Aetion

Stephanie Reisinger, Vice President and General Manager, Life Sciences, Veradigm Health

Debra A. Schaumberg, Vice President, Scientific Affairs, Evidera

Thomas Seck, Senior Vice President, Medicine & Regulatory Affairs, Boehringer Ingelheim

Lauren Silvis, Senior Vice President, Tempus

David Thompson, Senior Vice President, Syneos Health

Richard Wilke, Chief Science Officer, ISPOR

Marcus Wilson, Co-Founder and President, HealthCore



Jacqueline Corrigan-Curay, Director, Office of Medical Policy, CDER, U.S. Food and Drug Administration

Amanda Wagner-Gee, Program Officer, National Academies of Sciences, Engineering, and Medicine



A Framework for Regulatory Use of Real-World Evidence 

Characterizing RWD Quality and Relevancy for Regulatory Purposes

Determining Real-World Data’s Fitness for Use and the Role of Reliability

Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility

Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness

A Roadmap for Developing Study Endpoints in Real-World Settings


This project is made possible through the generosity of the Margolis Family Foundation, which provides core resources for the Center, as well as a combination of financial and in-kind contributions from collaborative members including AbbVie; Amgen; Boehringer Ingelheim; Eli Lilly and Company; Genentech, a member of the Roche Group; GlaxoSmithKline; Merck; Novartis; Pfizer; and Teva.

Participation of private or non-profit organizations in Center activities does not imply an endorsement by Duke University or associated entities. As part of Duke University, Duke-Margolis honors the tradition of academic independence on the part of its faculty and scholars. Neither Duke nor the Margolis Center take partisan positions, but the individual members are free to speak their minds and express their opinions regarding important issues. Duke Margolis adheres to all institutional policies on research independence and conflict of interest.